Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients

OBJECTIVE: To assess the long-term effectiveness and safety of trastuzumab in adjuvant therapy for Chinese patients with early-stage human epidermal growth factor 2 (HER2)-positive breast cancer in a real-world setting. METHODS: This retrospective observational study analyzed the medical records of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Chin J Cancer Res
Glavni autori: Guo, Jihong, Li, Qing, Zhang, Pin, Yuan, Peng, Wang, Jiayu, Ma, Fei, Fan, Ying, Cai, Ruigang, Luo, Yang, Li, Qiao, Xu, Binghe
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2019
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856699/
https://ncbi.nlm.nih.gov/pubmed/31814680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2019.05.06
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items